The Medical Letter on Drugs and Therapeutics
Obiltoxaximab (Anthim) for Inhalational Anthrax
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved obiltoxaximab (Anthim – Elusys Therapeutics), a toxin-targeting monoclonal antibody, for treatment of inhalational anthrax in combination with antibacterial drugs and prophylaxis of inhalational anthrax when other therapies are unavailable or inappropriate. Raxibacumab, another monoclonal antibody, was approved earlier for the same indication.1 Like raxibacumab, obiltoxaximab is being manufactured only for the CDC national stockpile and is not available for commercial sale.

ANTHRAX — Inhalational anthrax, caused by inhalation of the spores of Bacillus anthracis, is a continuing concern because of its potential use as a bioterrorism agent. Death is caused by a toxin, so treatment must include both antimicrobials and antitoxins. In the 2001 anthrax attacks in the US, 5 of 11 patients who contracted inhalational anthrax died despite ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Obiltoxaximab (Anthim) for Inhalational Anthrax
Article code: 1555d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian